Skip Navigation

European Heart Journal 2004 25(20):1769-1771; doi:10.1016/j.ehj.2004.08.008
Copyright © 2004 by the European Society of Cardiology.
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gresele, P.
Right arrow Articles by Migliacci, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gresele, P.
Right arrow Articles by Migliacci, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath?

Paolo Gresele* and Rino Migliacci

Department of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Via Enrico dal Pozzo, 06126 Perugia, Italy

Received August 6, 2004; revised August 6, 2004; accepted August 12, 2004 * Correspondence to: Prof. Paolo Gresele Department of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia. Via Enrico dal Pozzo, 06126 Perugia, Italy. Tel.: 075/5783989; fax: 075/5716083 (E-mail: grespa@unipg.it).

The first 10% of the full text of this article appears below.

This editorial refers to "Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2 year mortality in diabetics with peripheral arterial disease: the DAVID study"" by GGN Serneri et al. on page 1845.

It is only in the last decade or so that peripheral arterial disease (PAD) has come to the general attention of clinicians as a condition that can greatly increase the risk of ischaemic cardiovascular events and mortality, and it is only lately that actions have been undertaken to increase the awareness of this clinical condition and to institute appropriate therapies aimed at reducing the incidence of adverse cardiovascular events. Thus, PAD has rapidly transformed from a largely overlooked condition, managed solely by a 5-word prescription (stop smoking and go walking), to a disease requiring multi-therapeutic interventions and extensive programmes of detection.

The initial lack of attention to these patients is witnessed by . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study
Gian Gastone Neri Serneri, Sergio Coccheri, Ettore Marubini, Francesco Violi, and for the Committees and the Investigators of the Drug Evaluation in Atherosclerotic Vascular Disease in Diabetics Study Group
EHJ 2004 25: 1845-1852. [Abstract] [FREE Full Text]